Vaginal Royal Jelly for Vulvovaginal Candidiasis Treatment: A Randomized Clinical Trial

Background: Vulvovaginal Candidiasis (VVC) is a prevalent and complex health issue in women. With the rising resistance to synthetic antifungal medications, there is a growing emphasis on exploring natural remedies that minimize disruption to the normal vaginal flora. The goal of this study is to ev...

Full description

Saved in:
Bibliographic Details
Main Authors: Maryam Ramazany Chaleshtori, Mahmoodreza Madadian, Azadeh Akbari Sane, Farahnaz Farzaneh, Vida Kazemi, Fatemeh Montazer, Susan Sarhadi, Maryam Taghavi Shirazi, Shahla Mirgaloybayat
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2025-04-01
Series:Advanced Biomedical Research
Subjects:
Online Access:https://journals.lww.com/10.4103/abr.abr_69_24
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850042286657765376
author Maryam Ramazany Chaleshtori
Mahmoodreza Madadian
Azadeh Akbari Sane
Farahnaz Farzaneh
Vida Kazemi
Fatemeh Montazer
Susan Sarhadi
Maryam Taghavi Shirazi
Shahla Mirgaloybayat
author_facet Maryam Ramazany Chaleshtori
Mahmoodreza Madadian
Azadeh Akbari Sane
Farahnaz Farzaneh
Vida Kazemi
Fatemeh Montazer
Susan Sarhadi
Maryam Taghavi Shirazi
Shahla Mirgaloybayat
author_sort Maryam Ramazany Chaleshtori
collection DOAJ
description Background: Vulvovaginal Candidiasis (VVC) is a prevalent and complex health issue in women. With the rising resistance to synthetic antifungal medications, there is a growing emphasis on exploring natural remedies that minimize disruption to the normal vaginal flora. The goal of this study is to evaluate the efficacy of vaginal Royal Jelly (RJ) compared with clotrimazole for VVC treatment. Materials and Methods: This single-blind randomized clinical trial was conducted from 2020 to 2022 at Iran University of Medical Sciences hospitals, involving a total of 90 patients diagnosed with vaginal candidiasis. Positive vaginal culture individuals were randomly allocated to receive either vaginal 1000 mg RJ soft gel capsules or (2%) Clotrimazole cream (45 participants per group). Clinical signs, symptoms, and laboratory tests were statistically compared at baseline and ten days post-treatment. The data were analyzed using the independent t-tests, Mann-Whitney, Chi-square, and Wilcoxon tests through SPSS version 22. Results: After 10 days of treatment, both groups demonstrated a significant decrease in Candida culture results (P < 0.001). RJ also positively impacted vaginal symptoms such as itching, discharge, and burning. Moreover, most patients in both groups became asymptomatic post-treatment. Conclusions: The present study points out the therapeutic effects of vaginal RJ, a novel natural drug for improving VVC.
format Article
id doaj-art-f11a1c47be564b3daa71764a04395c8c
institution DOAJ
issn 2277-9175
language English
publishDate 2025-04-01
publisher Wolters Kluwer Medknow Publications
record_format Article
series Advanced Biomedical Research
spelling doaj-art-f11a1c47be564b3daa71764a04395c8c2025-08-20T02:55:36ZengWolters Kluwer Medknow PublicationsAdvanced Biomedical Research2277-91752025-04-01141323210.4103/abr.abr_69_24Vaginal Royal Jelly for Vulvovaginal Candidiasis Treatment: A Randomized Clinical TrialMaryam Ramazany ChaleshtoriMahmoodreza MadadianAzadeh Akbari SaneFarahnaz FarzanehVida KazemiFatemeh MontazerSusan SarhadiMaryam Taghavi ShiraziShahla MirgaloybayatBackground: Vulvovaginal Candidiasis (VVC) is a prevalent and complex health issue in women. With the rising resistance to synthetic antifungal medications, there is a growing emphasis on exploring natural remedies that minimize disruption to the normal vaginal flora. The goal of this study is to evaluate the efficacy of vaginal Royal Jelly (RJ) compared with clotrimazole for VVC treatment. Materials and Methods: This single-blind randomized clinical trial was conducted from 2020 to 2022 at Iran University of Medical Sciences hospitals, involving a total of 90 patients diagnosed with vaginal candidiasis. Positive vaginal culture individuals were randomly allocated to receive either vaginal 1000 mg RJ soft gel capsules or (2%) Clotrimazole cream (45 participants per group). Clinical signs, symptoms, and laboratory tests were statistically compared at baseline and ten days post-treatment. The data were analyzed using the independent t-tests, Mann-Whitney, Chi-square, and Wilcoxon tests through SPSS version 22. Results: After 10 days of treatment, both groups demonstrated a significant decrease in Candida culture results (P < 0.001). RJ also positively impacted vaginal symptoms such as itching, discharge, and burning. Moreover, most patients in both groups became asymptomatic post-treatment. Conclusions: The present study points out the therapeutic effects of vaginal RJ, a novel natural drug for improving VVC.https://journals.lww.com/10.4103/abr.abr_69_24clotrimazoleroyal jellyvulvovaginal candidiasis
spellingShingle Maryam Ramazany Chaleshtori
Mahmoodreza Madadian
Azadeh Akbari Sane
Farahnaz Farzaneh
Vida Kazemi
Fatemeh Montazer
Susan Sarhadi
Maryam Taghavi Shirazi
Shahla Mirgaloybayat
Vaginal Royal Jelly for Vulvovaginal Candidiasis Treatment: A Randomized Clinical Trial
Advanced Biomedical Research
clotrimazole
royal jelly
vulvovaginal candidiasis
title Vaginal Royal Jelly for Vulvovaginal Candidiasis Treatment: A Randomized Clinical Trial
title_full Vaginal Royal Jelly for Vulvovaginal Candidiasis Treatment: A Randomized Clinical Trial
title_fullStr Vaginal Royal Jelly for Vulvovaginal Candidiasis Treatment: A Randomized Clinical Trial
title_full_unstemmed Vaginal Royal Jelly for Vulvovaginal Candidiasis Treatment: A Randomized Clinical Trial
title_short Vaginal Royal Jelly for Vulvovaginal Candidiasis Treatment: A Randomized Clinical Trial
title_sort vaginal royal jelly for vulvovaginal candidiasis treatment a randomized clinical trial
topic clotrimazole
royal jelly
vulvovaginal candidiasis
url https://journals.lww.com/10.4103/abr.abr_69_24
work_keys_str_mv AT maryamramazanychaleshtori vaginalroyaljellyforvulvovaginalcandidiasistreatmentarandomizedclinicaltrial
AT mahmoodrezamadadian vaginalroyaljellyforvulvovaginalcandidiasistreatmentarandomizedclinicaltrial
AT azadehakbarisane vaginalroyaljellyforvulvovaginalcandidiasistreatmentarandomizedclinicaltrial
AT farahnazfarzaneh vaginalroyaljellyforvulvovaginalcandidiasistreatmentarandomizedclinicaltrial
AT vidakazemi vaginalroyaljellyforvulvovaginalcandidiasistreatmentarandomizedclinicaltrial
AT fatemehmontazer vaginalroyaljellyforvulvovaginalcandidiasistreatmentarandomizedclinicaltrial
AT susansarhadi vaginalroyaljellyforvulvovaginalcandidiasistreatmentarandomizedclinicaltrial
AT maryamtaghavishirazi vaginalroyaljellyforvulvovaginalcandidiasistreatmentarandomizedclinicaltrial
AT shahlamirgaloybayat vaginalroyaljellyforvulvovaginalcandidiasistreatmentarandomizedclinicaltrial